Last reviewed · How we verify
durvalumab and vactosertib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
durvalumab and vactosertib (durvalumab and vactosertib) — Hark Kyun Kim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| durvalumab and vactosertib TARGET | durvalumab and vactosertib | Hark Kyun Kim | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- durvalumab and vactosertib CI watch — RSS
- durvalumab and vactosertib CI watch — Atom
- durvalumab and vactosertib CI watch — JSON
- durvalumab and vactosertib alone — RSS
Cite this brief
Drug Landscape (2026). durvalumab and vactosertib — Competitive Intelligence Brief. https://druglandscape.com/ci/durvalumab-and-vactosertib. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab